Brexanolone Quiz

Q1. Brexanolone is primarily indicated for the treatment of which condition?

A) Postpartum depression

B) Bipolar disorder

C) Generalized anxiety disorder

D) Major depressive disorder

Q2. Answer: A What is the duration of the continuous intravenous infusion required for Brexanolone treatment?

A) 24 hours

B) 48 hours

C) 60 hours

D) 72 hours

Q3. Which serious side effect necessitates continuous monitoring during Brexanolone infusion?

A) Excessive sedation

B) Hypertension

C) Seizures

D) Hepatotoxicity

Q4. Which receptor is primarily targeted by Brexanolone to exert its therapeutic effects?

A) GABA-A receptor

B) NMDA receptor

C) Dopamine receptor

D) Serotonin receptor

Q5. Brexanolone is contraindicated in patients with which of the following conditions?

A) Severe hepatic impairment

B) Moderate renal impairment

C) Bipolar disorder

D) All of the above

Q6. What is the black box warning associated with Brexanolone?

A) Increased risk of suicidal ideation and behavior

B) Hepatotoxicity

C) Risk of serotonin syndrome

D) QT prolongation

Q7. What is a common side effect reported with Brexanolone use?

A) Sedation

B) Weight gain

C) Hypertension

D) Insomnia

Q8. Which monitoring tool is recommended during Brexanolone infusion to detect hypoxia?

A) Pulse oximetry

B) Electrocardiogram (ECG)

C) Continuous blood pressure monitor

D) Capnography

Q9. Which of the following augmentation strategies may be used with Brexanolone for partial response?

A) SSRIs

B) Lithium

C) Antipsychotics

D) All of the above

Q10. Which enzyme pathway is primarily responsible for the metabolism of Brexanolone?

A) Non-CYP based pathways

B) CYP2D6

C) CYP3A4

D) CYP1A2

Brexanolone (Zulresso) Medication